DE3770465D1 - Verwendung von zinn-protoporphyrin und zinn-mesoporphyrin zur herstellung eines arzneimittels fuer die behandlung von psoriasis. - Google Patents

Verwendung von zinn-protoporphyrin und zinn-mesoporphyrin zur herstellung eines arzneimittels fuer die behandlung von psoriasis.

Info

Publication number
DE3770465D1
DE3770465D1 DE8888900434T DE3770465T DE3770465D1 DE 3770465 D1 DE3770465 D1 DE 3770465D1 DE 8888900434 T DE8888900434 T DE 8888900434T DE 3770465 T DE3770465 T DE 3770465T DE 3770465 D1 DE3770465 D1 DE 3770465D1
Authority
DE
Germany
Prior art keywords
tin
mesoporphyrine
protoporphyrine
producing
medicinal product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8888900434T
Other languages
German (de)
English (en)
Inventor
Attallah York Avenue Kappas
S Drummond
Lennart Department Of Emtestam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Application granted granted Critical
Publication of DE3770465D1 publication Critical patent/DE3770465D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE8888900434T 1986-12-08 1987-12-07 Verwendung von zinn-protoporphyrin und zinn-mesoporphyrin zur herstellung eines arzneimittels fuer die behandlung von psoriasis. Expired - Lifetime DE3770465D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93882286A 1986-12-08 1986-12-08
US07/125,011 US4782049A (en) 1986-12-08 1987-12-02 Tin protoporphyrin and tin mesoporphyrin in the treatment of psoriasis
PCT/US1987/003248 WO1988004174A1 (en) 1986-12-08 1987-12-07 Use of tin protoporphyrin and tin mesoporphyrin in the treatment of psoriasis

Publications (1)

Publication Number Publication Date
DE3770465D1 true DE3770465D1 (de) 1991-07-04

Family

ID=26823181

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8888900434T Expired - Lifetime DE3770465D1 (de) 1986-12-08 1987-12-07 Verwendung von zinn-protoporphyrin und zinn-mesoporphyrin zur herstellung eines arzneimittels fuer die behandlung von psoriasis.

Country Status (12)

Country Link
US (1) US4782049A (enExample)
EP (1) EP0295280B1 (enExample)
JP (1) JPH01501627A (enExample)
KR (1) KR920002330B1 (enExample)
AT (1) ATE63815T1 (enExample)
AU (1) AU597144B2 (enExample)
CA (1) CA1302253C (enExample)
DE (1) DE3770465D1 (enExample)
DK (1) DK443088D0 (enExample)
IE (1) IE63507B1 (enExample)
PH (1) PH25224A (enExample)
WO (1) WO1988004174A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR890701108A (ko) * 1987-09-08 1989-12-19 원본미기재 종양요법의 독성효과를 반전시키기 위한 메탈로포르피린의 사용
GR1000182B (el) * 1988-03-28 1992-01-20 Univ Rockefeller Χρησιμοποιηση πρωτοπορφυρινης κασσιτερου και μεσοπορφυρινης κασσιτερου στην παρασευη φαρμακευτικων συνθεσεων για την αγωγη της ψωριασης.
US4997828A (en) * 1989-02-14 1991-03-05 The Rockefeller University Method of weight control by low level administration of cobalt protoporphyrin or cobalt mesoporphyrin
US5192757A (en) * 1990-12-20 1993-03-09 Glaxo Inc. Cobalt porphyrins
US5149697A (en) * 1991-04-18 1992-09-22 Glaxo Inc. Cobalt porphyrin pharmaceutical compositions
TW247876B (en) 1993-12-28 1995-05-21 New York Blood Ct Inc Pharmaceutical compositions for prevention or treating HIV-1 or HIV-2 infection
WO1995017893A1 (en) * 1993-12-28 1995-07-06 New York Blood Center Methods for preventing or treating hiv-1 or hiv-2 infection
CA2191627A1 (en) * 1994-06-02 1995-12-14 Zvi Malik Synergistic antibiotic compositions containing a perphyrin and an antibiotic
FR2727862B1 (fr) * 1994-12-07 1997-03-28 Holzmann Stephane Produits cosmetiques et/ou d'hygiene corporelle et/ou dermatologiques constitues d'une phase aqueuse isotonique et/ou d'une phase aqueuse osmotique
US5929064A (en) * 1995-08-02 1999-07-27 Warner-Lambert Company Amino acid complexes of cobalt (III) mesoporphyrin IX and cobalt (III) protoporphyrin IX
US7375216B2 (en) * 2002-06-04 2008-05-20 Infacare Pharmaceutical Corporation Preparation of metal mesoporphyrin compounds
EP1509527B1 (en) 2002-06-04 2014-05-07 InfaCare Pharmaceutical Corporation Preparation of metal mesoporphyrin halide compounds
US20040097481A1 (en) * 2002-11-20 2004-05-20 Benjamin Levinson Water-soluble mesoporphyrin compounds and methods of preparation
US20060222668A1 (en) * 2005-04-01 2006-10-05 Wellspring Pharmaceutical Corporation Stannsoporfin compositions, drug products and methods of manufacture
EP2992886A1 (en) 2006-10-04 2016-03-09 InfaCare Pharmaceutical Corporation High-purity large-scale preparation of stannsoporfin
EP2691398B1 (en) 2011-03-30 2016-09-28 InfaCare Pharmaceutical Corporation Methods for synthesizing metal mesoporphyrins
AU2015324103C1 (en) 2014-09-29 2020-08-20 Fred Hutchinson Cancer Center Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
CA3225692A1 (en) * 2021-07-12 2023-01-19 Donald Jeffrey Keyser Metal protoporphyrin for treatment of bk virus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454152A (en) * 1980-05-07 1984-06-12 Hoffmann-La Roche Inc. Methoxsalen dosage forms
US4657902A (en) * 1985-03-25 1987-04-14 The Rockefeller University Therapeutic use of tin mesoporphyrin
US4692439A (en) * 1986-06-20 1987-09-08 The Rockefeller University Therapeutic use of tin diiododeuteroporphyrin

Also Published As

Publication number Publication date
AU1081288A (en) 1988-06-30
PH25224A (en) 1991-03-27
IE873323L (en) 1988-06-08
KR890700026A (ko) 1989-03-02
EP0295280A1 (en) 1988-12-21
IE63507B1 (en) 1995-05-03
EP0295280B1 (en) 1991-05-29
WO1988004174A1 (en) 1988-06-16
DK443088A (da) 1988-08-08
KR920002330B1 (ko) 1992-03-21
ATE63815T1 (de) 1991-06-15
DK443088D0 (da) 1988-08-08
US4782049A (en) 1988-11-01
JPH0585523B2 (enExample) 1993-12-07
JPH01501627A (ja) 1989-06-08
EP0295280A4 (en) 1989-02-21
AU597144B2 (en) 1990-05-24
CA1302253C (en) 1992-06-02

Similar Documents

Publication Publication Date Title
ATE63815T1 (de) Verwendung von zinn-protoporphyrin und zinnmesoporphyrin zur herstellung eines arzneimittels fuer die behandlung von psoriasis.
ATE127342T1 (de) Verwendung von modafinil zur herstellung eines antiischämischen arzneimittels.
DE69428130D1 (de) Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten
DE68905205D1 (de) Verwendung von igf-i zur herstellung eines praeparats fuer die behandlung und die verhuetung von nebeneffekten von hyperinsulinemia bei diabetikern behandelt mit insulin.
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
ES8306601A1 (es) Metodo y su correspondiente aparato para la estimulacion de procesos biologicos relacionados con la actividad celular.
ATE116848T1 (de) Verwendung von baclofen zur herstellung von arzneimitteln zur behandlung von angina pectoris.
DE69527052D1 (de) Verwendung von Wasser mit verringertem Deuterium-Gehalt zur Herstellung von hygienischen und kosmetischen Präparaten
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE184193T1 (de) Verwendung von n-acylaminoalkoholen zur herstellung eines arzneimittels zur behandlung von mastzellerkrankungen
ATE186834T1 (de) Verwendung von wirksamen mengen von aktiven stoffen zur behandlung von mischhaut
ATE99932T1 (de) Verwendung von pyrrolicloncarbonsaeurealkylestern zur herstellung eines arzneimittels zur behandlung von ichtyosis.
DE3683333D1 (de) Mittel zur behandlung von akne vulgaris und deren herstellung.
DE69826023D1 (de) Verwendung von substanzen mit oxytocinwirkung zur herstellung eines arzneimittels zur behandlung affektiver schmerzsyndrome
ATE83378T1 (de) Verwendung von 3'-azido-deoxythymidin zur herstellung eines arzneimittels zur behandlung von humanen brustcarzinomen.
ATE106736T1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
ATE79254T1 (de) Die verwendung von d-fenfluramin zur herstellung von arzneimitteln, zur behandlung von depressionen.
DE69026511D1 (de) Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis
DE69124609D1 (de) Verfahren zur Reinigung von komerziellen Karraghenanen
ATE143804T1 (de) Zusammensetzung zur behandlung von mastitis und metritis
ATE61524T1 (de) Verwendung von hyperoxygenierten oelen zur herstellung eines arzneimittells zur behandlung von herpes.
ATE192929T1 (de) Verwendung von dimeticon zur herstellung eines arzneimittels zur behandlung von aphthen und stomatitis
DE3776170D1 (de) Quelle ultravioletter strahlen und verwendung derselben in verfahren mit photochemischer reaktion.
DE3686097D1 (de) Verwendung von dopamin-agonisten zur herstellung eines arzneimittels zur behandlung von psychostimulant-sucht.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee